<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="54">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01625234</url>
  </required_header>
  <id_info>
    <org_study_id>X396-CLI-101</org_study_id>
    <nct_id>NCT01625234</nct_id>
  </id_info>
  <brief_title>Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xcovery Holding Company, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xcovery Holding Company, LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first human study to use X-396, a drug being developed for treatment of advanced
      cancers. The initial purpose of the study is to determine the largest amount of X-396 that
      can be safely given to humans (the maximum tolerated dose). Once the recommended Phase 2
      dose has been determined, an expansion phase will assess the preliminary anti-tumor activity
      of X-396 in ALK-positive non-small cell lung cancer. The study will also provide early
      information on how the body handles the drug (pharmacokinetics) and on the efficacy of
      X-396.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is the first study of X-396 in humans and the investigational drug will be given as a
      once or twice daily oral dose in 28 day cycles until there is disease progression or
      unacceptable safety issues. X-396 will be given to small groups of patients (1 - 6) at each
      dose level and the patients will be observed to see if there are any adverse safety effects.
      As long as there are no unacceptable safety issues after 28 days, the dose of X-396 will be
      increased for the next group of patients. This process will continue until the maximum
      tolerated dose (MTD) of X-396 is reached. Once the MTD is reached, up to 60 additional
      patients will also be given X-396 to further determine the activity of X-396 in patients
      with ALK-positive non-small cell lung cancer. These additional patients will be enrolled in
      the following 5 expansion cohorts: ALK TKI-naïve patients, patients that progressed on
      crizotinib, patients that progressed on one or more 2nd generation ALK TKIs (patients may or
      may not have also received prior crizotinib), patients with asymptomatic CNS metastases, and
      patients with leptomeningeal disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To evaluate the safety/tolerability of X-396 and determine the maximum tolerated dose (MTD) of X-396 as a single agent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations (Cmax, Tmax, AUC, half-life)</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To characterize the preliminary pharmacokinetics including Cmax, Tmax, AUC, half-life of X-396 given as a single agent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary Tumor Response</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To explore the preliminary clinical tumor response after treatment with X-396 given as a single agent.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>X-396</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation starting at 25 mg, oral once or twice a day, 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>X-396</intervention_name>
    <description>Oral, ALK inhibitor</description>
    <arm_group_label>X-396</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically confirmed diagnosis of advanced solid tumor
             malignancy. Patients may have received prior crizotinib and/or second generation ALK
             TKIs.

             -For the expanded cohort portion of the study, patients must have NSCLC with ALK
             genomic alterations positive by FISH or IHC testing done centrally; however, patients
             will be allowed to enroll based on local ALK FISH or IHC results.

          2. Eastern Cooperative Group ECOG) Performance Status score of 0 or 1.

          3. Ability to swallow and retain oral medication.

          4. Adequate organ system function.

          5. Patients with treated or untreated asymptomatic CNS metastases may be allowed to
             enroll.

          6. Male patients willing to use adequate contraceptive measures.

          7. Female patients who are not of child-bearing potential, and female patients of
             child-bearing potential who agree to use adequate contraceptive measures.

          8. Patients must be ≥ 18 years of age.

          9. Patients must have measurable or evaluable disease for the dose escalation portion of
             the study and measurable disease for the expanded cohort portion of the study (except
             for patients in the CNS metastases and leptomeningeal cohorts).

         10. Patients entering this study will be asked to provide tissue for correlative testing
             (if available).

         11. Willingness and ability to comply with the trial and follow-up procedures.

         12. Ability to understand the nature of this trial and give written informed consent.

        Exclusion Criteria:

          1. Patients currently receiving cancer therapy.

          2. Use of an investigational drug within 21 days or 5 half-lives (whichever is shorter)
             prior to the first dose of X-396.

          3. Any major surgery, radiotherapy, or immunotherapy within the last 21 days.
             Chemotherapy regimens with delayed toxicity within the last 4 weeks. Chemotherapy
             regimens given continuously or on a weekly basis with limited potential for delayed
             toxicity within the last 2 weeks.

          4. Prior stem cell transplant.

          5. Patients with a known allergy or delayed hypersensitivity reaction to drugs
             chemically related to X-396 (e.g., crizotinib) or to the active ingredient of X-396.

          6. Patients with primary CNS tumors are ineligible.

          7. Concomitant use of drugs with a risk of causing prolonged QTc and/or Torsades de
             Pointes.

          8. Concomitant use of herbal medications at least 7 days prior to the first dose of
             study drug and throughout participation in the trial.

          9. Females who are pregnant or breastfeeding.

         10. Presence of active gastrointestinal (GI) disease or other condition that will
             interfere significantly with the absorption, distribution, metabolism, or excretion
             of X-396.

         11. Clinically significant cardiovascular disease.

         12. Patients who are immunosuppressed (including known HIV infection), have a serious
             active infection at the time of treatment, have known hepatitis C, or have any
             serious underlying medical condition that would impair the ability of the patient to
             receive protocol treatment.

         13. Psychological, familial, sociological, or geographical conditions that do not permit
             compliance with the protocol.

         14. Concurrent condition that in the investigator's opinion would jeopardize compliance
             with the protocol or would impart excessive risk associated with study participation
             that would make it inappropriate for the patient to be enrolled.

         15. Inability or unwillingness to comply with study and/or follow-up procedures outlined
             in the protocol.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>City of Hope National Med Ctr</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roy Maya</last_name>
      <phone>626-256-4673</phone>
      <phone_ext>80115</phone_ext>
      <email>rmaya@coh.org</email>
    </contact>
    <investigator>
      <last_name>Karen Reckamp, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSD Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Hanan</last_name>
      <phone>858-822-6869</phone>
      <email>shanan@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Sandip Patel, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Cancer Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Sanchez</last_name>
      <phone>909-558-4050</phone>
    </contact>
    <investigator>
      <last_name>Hamid Mirshahidi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Tse</last_name>
      <phone>323-865-3962</phone>
      <email>tse_g@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Barbara Gitlitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Quick</last_name>
      <phone>650-723-2983</phone>
      <email>richardq@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Heather Wakelee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tausha Flux</last_name>
      <phone>813-745-6238</phone>
      <email>tausha.flux@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Alberto Chiappori, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginia (Ginger) Schmidt</last_name>
      <phone>301-295-6814</phone>
      <email>Virginia.f.schmidt3.ctr@mail.mil</email>
    </contact>
    <investigator>
      <last_name>Corey Carter, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryan Marion</last_name>
      <phone>617-632-3383</phone>
      <email>mailto:bryan_marion@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Leena Gandhi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Barbara Russell</last_name>
      <phone>507-538-0270</phone>
      <email>mailto:Russell.Barbara2@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Aaron Mansfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Meredith, MS, CCRP</last_name>
      <phone>314-362-4140</phone>
      <email>mmeredith@dom.wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ian McGowan</last_name>
      <phone>314-747-7569</phone>
      <email>imcgowan@dom.wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Saiama N Waqar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danny Paucar</last_name>
      <phone>718-405-8539</phone>
      <email>dpaucar@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Haiying Cheng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Cancer Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Lyktey</last_name>
      <phone>631-638-1000</phone>
      <email>Kim.Lyktey@stonybrookmedicine.edu</email>
    </contact>
    <investigator>
      <last_name>Roger Keresztes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Schweitzer</last_name>
      <phone>614-685-5414</phone>
      <email>Catherine.Schweitzer@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Otterson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Edwards</last_name>
      <phone>503-215-1833</phone>
      <email>nicole.edwards@providence.org</email>
    </contact>
    <investigator>
      <last_name>Rachel Sanborn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Miller</last_name>
      <phone>717-531-1003</phone>
      <email>rmiller13@hmc.psu.edu</email>
    </contact>
    <investigator>
      <last_name>Chandra Belani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay Hopkins</last_name>
      <phone>215-214-3789</phone>
      <email>Lindsay.Hopkins@fccc.edu</email>
    </contact>
    <investigator>
      <last_name>Renee Mehra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Dority</last_name>
      <phone>843-792-5853</phone>
      <email>dority@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Carol Sherman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ainslie Rogers</last_name>
      <phone>615-524-4155</phone>
      <email>ainslie.rogers@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Infante, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhonda Combs</last_name>
      <phone>800-811-8480</phone>
      <email>cip@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Leora Horn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Blumenschein</last_name>
      <phone>855-873-4321</phone>
    </contact>
    <investigator>
      <last_name>George Blumenschein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galina Diakova</last_name>
      <phone>434-924-5990</phone>
      <email>GBD4G@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Hall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University Hospital</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trish Beal</last_name>
      <phone>304-293-0609</phone>
      <email>pbeal@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick C Ma, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Carbone Cancer Ctr</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elise VolkmannVolkmann</last_name>
      <phone>608-262-8158</phone>
      <email>emvolkma@uwcarbone.wisc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Hilary R Hernan</last_name>
      <email>hrhernan@uwcarbone.wisc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ticiana Leal, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lovly CM, Heuckmann JM, de Stanchina E, Chen H, Thomas RK, Liang C, Pao W. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res. 2011 Jul 15;71(14):4920-31. doi: 10.1158/0008-5472.CAN-10-3879. Epub 2011 May 25.</citation>
    <PMID>21613408</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 28, 2016</lastchanged_date>
  <firstreceived_date>June 15, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Tumors</keyword>
  <keyword>ALK</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Advanced Malignancies</keyword>
  <keyword>Carcinoma, Non-Small-Cell Lung</keyword>
  <keyword>Inflammatory Myofibroblastic Tumors</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
